- Home
- PLRX vs CRMD Comparison
PLRX vs CRMD Comparison
Compare PLRX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | CRMD |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | 82 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 983.3M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | PLRX | CRMD |
|---|---|---|
| Price | $1.23 | $11.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $3.79 | ★ $17.43 |
| AVG Volume (30 Days) | 1.9M | ★ 2.7M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | N/A | ★ $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | N/A | $40.95 |
| P/E Ratio | ★ N/A | $5.54 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $1.10 | $5.60 |
| 52 Week High | $13.71 | $17.43 |
Technical Indicators
Market Signals| Indicator | PLRX | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 52.58 |
| Support Level | $1.20 | $11.78 |
| Resistance Level | $1.27 | $13.02 |
| Average True Range (ATR) | 0.06 | 0.47 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 22.58 | 36.36 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.